Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer

Int J Cardiol. 2012 Feb 9;154(3):341-4. doi: 10.1016/j.ijcard.2011.10.115. Epub 2011 Nov 9.

Authors

Christodoulos Stefanadis, Andreas Synetos, Dimitris Tousoulis, Eleftherios Tsiamis, Archontoula Michelongona, Flora Zagouri, Aristotle Bamias, Meletios Athanasios Dimopoulos, Stella Kyvelou, Ioannis Kapelakis, Konstantinos Toutouzas

PMID: 22078988
DOI: 10.1016/j.ijcard.2011.10.115

No abstract available

Publication types

Letter

MeSH terms

Aged
Angiogenesis Inhibitors / administration & dosage*
Angiogenesis Inhibitors / adverse effects
Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Humanized / adverse effects
Bevacizumab
Breast Neoplasms / drug therapy
Breast Neoplasms / pathology
Cardiovascular Diseases / chemically induced
Cardiovascular Diseases / epidemiology*
Colorectal Neoplasms / drug therapy
Colorectal Neoplasms / pathology
Female
Humans
Incidence
Male
Neoplasm Metastasis
Prognosis
Prospective Studies
Risk Factors

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Bevacizumab